Therapeutic efficacy and safety of combined BRAF and MEK inhibition in patients with malignant melanoma: a meta-analysis

@inproceedings{Chen2017TherapeuticEA,
  title={Therapeutic efficacy and safety of combined BRAF and MEK inhibition in patients with malignant melanoma: a meta-analysis},
  author={Peng Chen and Fuchao Chen and Benhong Zhou},
  booktitle={OncoTargets and therapy},
  year={2017}
}
Background Recent clinical studies have shown that initial therapy with combined BRAF and mitogen-activated extracellular signal-regulated kinase (MEK) inhibition is more effective in metastatic melanoma than single-agent BRAF inhibitors. However, the response rates with single-agent BRAF are low. Thus, the objective of this study was to conduct a meta-analysis of randomized controlled trials to compare the efficacy and adverse events risk between mono-therapy and combination therapy… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 30 REFERENCES

Improved overall survival in melanoma with combined dabrafenib and trametinib.

  • The New England journal of medicine
  • 2015
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.

  • The New England journal of medicine
  • 2014
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.

  • The New England journal of medicine
  • 2012
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2015
VIEW 1 EXCERPT
HIGHLY INFLUENTIAL

Similar Papers

Loading similar papers…